Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03437265
Other study ID # NER1006-03/2016 (PKPU)
Secondary ID 2017-003440-20
Status Completed
Phase Phase 1
First received
Last updated
Start date September 3, 2020
Est. completion date October 5, 2020

Study information

Verified date November 2023
Source Norgine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study characterises the pharmacokinetic (PK) profile of the active ingredients of PLENVU (NER1006) and their related substances/metabolites. Subjects will receive PLENVU.


Description:

PLENVU is a novel, low volume (1 L) PEG 3350 and ascorbate based bowel preparation that has been developed to provide whole bowel cleansing. Studies have shown that formulating the osmotically active agents sodium ascorbate/ascorbic acid (also known as vitamin C) and sodium sulfate in combination with PEG 3350 enable a reduction in the volume of the PEG-based lavage solution. PLENVU has a dual formulation containing an initial majority PEG dose followed by a majority ascorbate dose to maximise the overall effectiveness. This novel formulation addresses the challenges faced by patients to comply with drinking higher volume, 2 and 3 L, preparations. The purpose of this study is to determine if there is systemic exposure to components of the PLENVU formulation (PEG 3350, ascorbate and potential related substances/metabolites (oxalic acid, glycolic acid, ethylene glycol and diethylene glycol).


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date October 5, 2020
Est. primary completion date October 5, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: 1. Healthy males or non-pregnant, non-lactating healthy females 2. Age 18 to 30 years 3. BMI of 18.0 to 35.0 kg/m2 4. Must be willing and able to communicate and participate in the whole study 5. Must provide written informed consent 6. Must agree to use an adequate method of contraception Exclusion Criteria: 1. Subjects who have received any Investigational Medicinal Product (IMP) in a clinical research study within the previous 3 months 2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee 3. Subjects who have previously been enrolled in this study. 4. History of any drug or alcohol abuse in the past 2 years 5. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) 6. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening 7. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months 8. Females who are pregnant or lactating (all female subjects must have a negative urine pregnancy test at screening and admission). 9. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening 10. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator at screening 11. Evidence of dehydration or abnormal electrolyte levels. Clinical evidence or suspicion of significant dehydration at admission/pre-dose. 12. History or evidence of any clinically relevant ECG abnormality and hypertension 13. Positive drugs of abuse test result 14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results 15. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or psychiatric disorder, as judged by the investigator 16. History or presence of organic or functional gastrointestinal conditions (e.g. chronic constipation, inflammatory bowel disease or irritable bowel syndrome) 17. Previous or current relevant abnormal gastrointestinal motility according to clinical judgement 18. History or presence of any clinically significant acute illness within 28 days prior to the first dose of IMP based on clinical judgement at screening or admission 19. History of any of the contraindications mentioned in the PLENVU Summary of Product Characteristics (SmPC) 20. Clinically relevant findings on physical examination based on investigator judgement 21. Donation or loss of greater than 500 mL of blood within the previous 8 weeks 22. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than hormonal contraception and occasional use of non-steroidal anti-inflammatory drugs [NSAIDs] and paracetamol) or herbal remedies in the 28 days before IMP administration Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor. 23. Use of laxatives and gastrointestinal motility altering drug in the last 3 months 24. Evidence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 25. Subjects who are ordered to live in an institution on court or authority order 26. Failure to satisfy the investigator of fitness to participate for any other reason

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PLENVU powder for oral solution
PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)

Locations

Country Name City State
United Kingdom Quotient Sciences (Quotient), Ruddington Nottingham

Sponsors (2)

Lead Sponsor Collaborator
Norgine Quotient Sciences

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) Time of maximum observed concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the pharmacokinetic (PK) population. Blood samples were taken pre-dose and up to 60 hours after start of Dose 1
Primary T1/2 (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) Apparent elimination half-life (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population. Blood samples were taken pre-dose and up to 60 hours after start of Dose 1
Primary Cmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) The mean maximum observed concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population. Blood samples were taken pre-dose and up to 60 hours after start of Dose 1
Primary Area Under the Curve From 0 Time to 24 h Post-dose (AUC[0-24]) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) Area under the curve from 0 time to 24 h post-dose (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population. Blood samples were taken pre-dose and up to 60 hours after start of Dose 1
Primary AUC(0-last) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) Area under the curve from 0 time to the last measurable concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population. Blood samples were taken pre-dose and up to 60 hours after start of Dose 1
Primary AUC(0-inf) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) Area under the curve from 0 time extrapolated to infinity (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population. Blood samples were taken pre-dose and up to 60 hours after start of Dose 1
Secondary Timing and Number of Bowel Movements Pharmacodynamic outcome. The time of each bowel movement will be recorded for each subject, and the number of bowel movements after each dose per subject will be derived. Start of dose 1 to 60 hours
Secondary Time to Achieve Clear Effluent Pharmacodynamic outcome. Scoring was according to a 4-point scale (adapted from the stool characteristics rating tool described by Hsu et al, Adv Dig Med. 2016; 3 (3):144-147).
A. Clear contents (may be coloured but able to visualise the bottom of the toilet bowl) B. Turbid contents C. Opaque contents (dark and murky) D. Any solid/semi-solid faecal material (irrespective of size) in the toilet bowl
Start of dose 1 to 60 hours
See also
  Status Clinical Trial Phase
Completed NCT04531150 - Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects Phase 1
Completed NCT03979989 - Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol) Phase 1
Completed NCT00743912 - Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers Phase 1
Not yet recruiting NCT05367011 - Therapeutic Monitoring of Antibiotics in Intensive Care Patients: a Cohort Study PopTDM-ICU
Completed NCT06126562 - A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects Phase 1
Completed NCT00745264 - Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise Phase 1
Completed NCT03344627 - Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients N/A
Completed NCT01082796 - Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects N/A
Terminated NCT02696954 - Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects Phase 1/Phase 2
Recruiting NCT03714568 - Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants. Phase 1
Recruiting NCT04080895 - Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects Phase 1
Active, not recruiting NCT04735913 - Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults Early Phase 1
Completed NCT03011996 - To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration Phase 1
Completed NCT00681395 - Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium Phase 1
Completed NCT04617509 - A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 Phase 1
Terminated NCT03059511 - Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants Phase 1
Withdrawn NCT05938608 - A Study to Assess the Availability of Oral Primaquine and Its Inert Metabolite, Carboxyprimaquine, in the Body Phase 1
Completed NCT01091532 - A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects. Phase 1
Completed NCT03951402 - Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women Phase 1
Completed NCT03882762 - A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol Phase 1